The latest price target for Assembly Biosciences (NASDAQ:ASMB) was reported by HC Wainwright & Co. on September 24, 2024. The analyst firm set a price target for $0.00 expecting ASMB to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Assembly Biosciences (NASDAQ:ASMB) was provided by HC Wainwright & Co., and Assembly Biosciences reiterated their neutral rating.

The last upgrade for Assembly Biosciences Inc happened on September 20, 2024 when Jefferies raised their price target to $35. Jefferies previously had a hold for Assembly Biosciences Inc.

The last downgrade for Assembly Biosciences Inc happened on October 24, 2022 when Truist Securities changed their price target from $11 to $2 for Assembly Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Assembly Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Assembly Biosciences was filed on September 24, 2024 so you should expect the next rating to be made available sometime around September 24, 2025.

While ratings are subjective and will change, the latest Assembly Biosciences (ASMB) rating was a reiterated with a price target of $0.00 to $0.00. The current price Assembly Biosciences (ASMB) is trading at is $16.06, which is out of the analyst’s predicted range.